JPS59110625A - プラスミノ−ゲン活性化因子、その製造法およびその製造用生産物 - Google Patents
プラスミノ−ゲン活性化因子、その製造法およびその製造用生産物Info
- Publication number
- JPS59110625A JPS59110625A JP58005148A JP514883A JPS59110625A JP S59110625 A JPS59110625 A JP S59110625A JP 58005148 A JP58005148 A JP 58005148A JP 514883 A JP514883 A JP 514883A JP S59110625 A JPS59110625 A JP S59110625A
- Authority
- JP
- Japan
- Prior art keywords
- tissue plasminogen
- plasminogen activator
- precursor
- tpa
- plasmin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013566 Plasminogen Human genes 0.000 title claims description 17
- 108010051456 Plasminogen Proteins 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 230000003213 activating effect Effects 0.000 title description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 73
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 73
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 73
- 239000002243 precursor Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 37
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 37
- 229960005356 urokinase Drugs 0.000 claims description 37
- 239000003112 inhibitor Substances 0.000 claims description 35
- 108010088842 Fibrinolysin Proteins 0.000 claims description 32
- 229940012957 plasmin Drugs 0.000 claims description 32
- 239000012736 aqueous medium Substances 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 229940088598 enzyme Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 14
- 229940127126 plasminogen activator Drugs 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 108090000631 Trypsin Proteins 0.000 claims description 11
- 102000004142 Trypsin Human genes 0.000 claims description 11
- 239000012588 trypsin Substances 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 241000219766 Erythrina Species 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000003480 fibrinolytic effect Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 241000219769 Erythrina latissima Species 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 7
- 239000000356 contaminant Substances 0.000 claims description 7
- 238000003795 desorption Methods 0.000 claims description 7
- 230000002797 proteolythic effect Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000033885 plasminogen activation Effects 0.000 claims description 6
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 6
- 229940116357 potassium thiocyanate Drugs 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 4
- 230000020764 fibrinolysis Effects 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229940122791 Plasmin inhibitor Drugs 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000002806 plasmin inhibitor Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 229960001322 trypsin Drugs 0.000 claims 3
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 102000009123 Fibrin Human genes 0.000 description 15
- 108010073385 Fibrin Proteins 0.000 description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 15
- 229950003499 fibrin Drugs 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229920000936 Agarose Polymers 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108010023197 Streptokinase Proteins 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229960005202 streptokinase Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 101100084404 Mus musculus Prodh gene Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101710082148 Trypsin alpha Proteins 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QLDYTACVSNAPTO-UHFFFAOYSA-N [N-]=[N+]=NSN=[N+]=[N-] Chemical compound [N-]=[N+]=NSN=[N+]=[N-] QLDYTACVSNAPTO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA829168 | 1982-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59110625A true JPS59110625A (ja) | 1984-06-26 |
| JPH0223158B2 JPH0223158B2 (enrdf_load_stackoverflow) | 1990-05-23 |
Family
ID=25576429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58005148A Granted JPS59110625A (ja) | 1982-12-14 | 1983-01-13 | プラスミノ−ゲン活性化因子、その製造法およびその製造用生産物 |
| JP58237136A Granted JPS59118717A (ja) | 1982-12-14 | 1983-12-14 | プラスミノーゲン活性化剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58237136A Granted JPS59118717A (ja) | 1982-12-14 | 1983-12-14 | プラスミノーゲン活性化剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JPS59110625A (enrdf_load_stackoverflow) |
| AU (1) | AU554862B2 (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62116600A (ja) * | 1985-10-04 | 1987-05-28 | サウスアフリカン・インヴエンシヨンズ・デイヴエロツプメント・コ−ポレ−シヨン | 試薬および方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA831399B (en) * | 1982-03-05 | 1984-02-29 | Health Lab Service Board | New fibrinolytic enzymes and methods for their production and pharmaceutical compositions containing them |
| DK175327B1 (da) * | 1984-10-01 | 2004-08-23 | Integrated Genetics Inc | Replicerbar ekspressionsvektor og rekombinant DNA-molekyle, som indkoder aktiv human livmodervævsplasminogen-aktivator, pattedyrscelle transformeret med vektoren og fremgangsmåde til fremstilling af aktiv human vævsplasminogen-aktivator (TPA) |
| GB2176703B (en) * | 1985-05-28 | 1988-12-07 | Wellcome Found | Novel formulation |
| US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
| GB8513358D0 (en) * | 1985-05-28 | 1985-07-03 | Wellcome Found | Formulation |
| JPS6463378A (en) * | 1986-08-11 | 1989-03-09 | Mitsui Toatsu Chemicals | Separation of single stranded tpa and double standard tpa |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8003402A (nl) * | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking. |
| ZA833174B (en) * | 1982-05-05 | 1984-08-29 | Genentech Inc | Human tissue plasminogen activator |
| JPS5913732A (ja) * | 1982-07-16 | 1984-01-24 | Mitsui Toatsu Chem Inc | 血栓溶解剤 |
-
1983
- 1983-01-11 AU AU10296/83A patent/AU554862B2/en not_active Expired
- 1983-01-13 JP JP58005148A patent/JPS59110625A/ja active Granted
- 1983-12-14 JP JP58237136A patent/JPS59118717A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62116600A (ja) * | 1985-10-04 | 1987-05-28 | サウスアフリカン・インヴエンシヨンズ・デイヴエロツプメント・コ−ポレ−シヨン | 試薬および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1029683A (en) | 1984-06-21 |
| JPH0223158B2 (enrdf_load_stackoverflow) | 1990-05-23 |
| JPS59118717A (ja) | 1984-07-09 |
| AU554862B2 (en) | 1986-09-04 |
| JPH0570607B2 (enrdf_load_stackoverflow) | 1993-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4902623A (en) | Plasminogen activator | |
| JP4385097B2 (ja) | 蛋白質溶液からのプラスミノゲン（プラスミン）の除去 | |
| JPH0378375B2 (enrdf_load_stackoverflow) | ||
| JP2002518411A (ja) | 薬学的第ｖｉｉ因子調製物 | |
| JPH02504587A (ja) | ７ａ因子に富む画分の製造方法及び医薬としてのその用途 | |
| FI96211B (fi) | Menetelmä yksisäikeisen kudosplasminogeeniaktivaattorin (tPA) ja kaksisäikeisen tPA:n puhdistamiseksi ja eristämiseksi | |
| JPS59110625A (ja) | プラスミノ−ゲン活性化因子、その製造法およびその製造用生産物 | |
| US6001355A (en) | Pro-tPA for the treatment of thrombosis, embolism and related conditions | |
| TW385313B (en) | Method for the production of rDSPA alpha 1 | |
| WO1981001417A1 (en) | Isolation of plasminogen activators useful as therapeutic and diagnostic agents | |
| JPS62116600A (ja) | 試薬および方法 | |
| JPS6229975A (ja) | 粗ｔＰＡの精製法 | |
| JPH10158300A (ja) | 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法 | |
| Tamura et al. | Purification of human plasma kallikrein and urokinase by affinity chromatography | |
| JPH0556951B2 (enrdf_load_stackoverflow) | ||
| JPH07291999A (ja) | 血小板安定化因子ｉｘ−フラグメント、その製造方法及びこれを含有する薬剤 | |
| CA1333163C (en) | Methods for the recovery of tissue plasminogen activator | |
| JPH0260316B2 (enrdf_load_stackoverflow) | ||
| JP2714817B2 (ja) | ウロキナーゼ前駆体の製造方法 | |
| CA2245554C (en) | Method for the production of rdspa .alpha.1 | |
| JPH0723397B2 (ja) | 人尿トリプシンインヒビターおよび人尿カリクレインの濃縮分離方法 | |
| JPH03219871A (ja) | セリンプロテアーゼ | |
| JPS6092220A (ja) | カリクレインの精製法 | |
| Thorsen et al. | The influence of fibrin on the kinetics of inhibition of tissue-type (T-PA) or urokinase type plasminogen activator (U-PA) by plasminogen-activator inhibitor of type 1 (PAI-1) or type 2 (PAI-2) | |
| JPS62153225A (ja) | ブタ膵臓性カリクレインの精製法 |